Tuberculosis and Respiratory Diseases
- 제48권6호
- /
- Pages.964-972
- /
- 2000
- /
- 1738-3536(pISSN)
- /
- 2005-6184(eISSN)
타카야수동맥염에 의한 만성 폐고혈압에서 Nitric Oxide가스와 Molsidomine의 치험 3예
Role of Nitric Oxide and Molsidomine in the Management of Pulmonary Hypertension in Takayasu's Arteritis
- 진재용 (인제대학교 의과대학 일산백병원 내과) ;
- 이성순 (울산대학교 의과대학, 서울중앙병원 호흡기내과) ;
- 이상수 (울산대학교 의과대학, 서울중앙병원 호흡기내과) ;
- 심태선 (울산대학교 의과대학, 서울중앙병원 호흡기내과) ;
-
임채만
(울산대학교 의과대학, 서울중앙병원 호흡기내과) ;
-
고윤석
(울산대학교 의과대학, 서울중앙병원 호흡기내과) ;
- 김우성 (울산대학교 의과대학, 서울중앙병원 호흡기내과) ;
- 김동순 (울산대학교 의과대학, 서울중앙병원 호흡기내과) ;
- 김원동 (울산대학교 의과대학, 서울중앙병원 호흡기내과) ;
-
이상도
(울산대학교 의과대학, 서울중앙병원 호흡기내과)
- Chin, Jae-Yong ;
- Lee, Sung-Soon (Department of Internal medicine, Asan Medical Center, University of Ulsan College of Medicine) ;
- Lee, Sang-Soo (Department of Internal medicine, Asan Medical Center, University of Ulsan College of Medicine) ;
- Shim, Tae-Sun (Department of Internal medicine, Asan Medical Center, University of Ulsan College of Medicine) ;
-
Lim, Chae-Man
(Department of Internal medicine, Asan Medical Center, University of Ulsan College of Medicine) ;
-
Koh, Youn-Suck
(Department of Internal medicine, Asan Medical Center, University of Ulsan College of Medicine) ;
- Kim, Woo-Sung (Department of Internal medicine, Asan Medical Center, University of Ulsan College of Medicine) ;
- Kim, Dong-Soon (Department of Internal medicine, Asan Medical Center, University of Ulsan College of Medicine) ;
- Kim, Won-Dong (Department of Internal medicine, Asan Medical Center, University of Ulsan College of Medicine) ;
-
Lee, Sang-Do
(Department of Internal medicine, Asan Medical Center, University of Ulsan College of Medicine)
- 발행 : 2000.06.30
초록
저자들은 타카야수동맥염에 의한 만성 폐고혈압 환자 3예를 대상으로 혈관확장제 (NO 및 molsidomine)가 이들의 폐고혈압을 완화시킬 수도 있음을 관찰하였으며, 이와 관련하여 보다 많은 연구가 이루어져야 하리라 생각된다.
We report three patients with pulmonary hypertension in Takayasu's arteritis, who showed long-term favorable response, clinically and hemodynamically, to the nitric oxide donor, molsidomine. In these patients, the inhaled nitric oxide was effective in reducing pulmonary artery pressure (PAP) and pulmonary vascular resistance (PVR) as was shown in the acute vasodilator response test using the invasive hemodynamic monitoring. Molsidomine (single oral dose of 4 mg) was also effective in reducing PAP and PVR in the acute test, but nifedipine was not. With 4 mg of molsidomine three times daily, their dyspnea, exercise capacity and hemodynamic parameters were improved. These favorable responses have lasted during the 1st and 3rd month follow-up in all patients.